Embecta (NASDAQ:EMBC – Get Free Report) is expected to post its Q3 2026 results before the market opens on Friday, August 7th. Analysts expect Embecta to announce earnings of $0.26 per share and revenue of $254.5260 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:00 AM ET.
Embecta (NASDAQ:EMBC – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.15). The firm had revenue of $221.80 million during the quarter, compared to the consensus estimate of $235.67 million. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The firm’s revenue was down 14.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.70 EPS. On average, analysts expect Embecta to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Embecta Stock Down 6.4%
NASDAQ EMBC opened at $3.58 on Thursday. Embecta has a 52 week low of $2.77 and a 52 week high of $15.55. The business has a 50 day moving average price of $3.32 and a 200-day moving average price of $6.74. The company has a market cap of $212.10 million, a price-to-earnings ratio of 1.88 and a beta of 0.81.
Institutional Trading of Embecta
Key Headlines Impacting Embecta
Here are the key news stories impacting Embecta this week:
- Neutral Sentiment: Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, have until August 17, 2026 to seek appointment as lead plaintiff. The notices from Kaplan Fox, Levi & Korsinsky, Faruqi & Faruqi, and other firms are soliciting affected shareholders and do not establish that the allegations are true. Kaplan Fox Embecta class action notice
- Negative Sentiment: The pending lawsuit alleges that Embecta and certain executives misrepresented the commercial stability and strength of its insulin pen needle business, potentially misleading investors about the company’s outlook. Embecta securities fraud class action
- Negative Sentiment: Law-firm notices link the litigation to an approximately 57% stock collapse and allegations that Embecta cut its earnings outlook after reporting a major revenue deterioration. One investor alert says the company had previously forecast revenue that was flat to down 2% and EPS of $2.80–$3.00, before reporting a revenue decline of roughly 17.4% and reducing guidance by nearly half. Embecta shareholder alert
- Negative Sentiment: The legal overhang adds potential litigation costs, management distraction, and uncertainty around Embecta’s disclosures and future performance. This is particularly concerning alongside the company’s recent earnings miss, falling revenue, and stock trading close to its one-year low.
Wall Street Analyst Weigh In
EMBC has been the subject of several research reports. Mizuho reduced their price target on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. BTIG Research lowered shares of Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Weiss Ratings cut shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday. Wall Street Zen downgraded shares of Embecta from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Bank of America lowered their target price on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a report on Monday, May 18th. Three research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $11.00.
Check Out Our Latest Stock Analysis on Embecta
About Embecta
Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.
The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.
Featured Stories
- Five stocks we like better than Embecta
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
